AIMS/HYPOTHESIS: We followed type 2 diabetic patients over a long period to evaluate the predictive value of ambulatory pulse pressure (PP) and decreased nocturnal BP reduction (non-dipping) for nephropathy progression. METHODS: Type 2 diabetic patients (n = 112) were followed for an average of 9.5 (range 0.5-14.5) years. At baseline, all patients underwent 24 h ambulatory BP measurement. Urinary albumin excretion rate was evaluated by three urinary albumin:creatinine ratio measurements at baseline and follow-up. RESULTS: At baseline, patients who subsequently progressed to a more advanced nephropathy stage (n = 35) had reduced diastolic night/day BP variation and higher 24 h systolic BP and PP values; they also had more advanced nephropathy and were more likely to smoke than those with no progression of nephropathy (n = 77). In a Cox regression analysis, independent predictors of nephropathy progression were 24 h PP (p < 0.01), diastolic night:day BP ratio (p = 0.02) and smoking (p = 0.02). The adjusted hazards ratio (95% CI) for each mmHg increment in 24 h PP was 1.04 (1.01-1.07), whereas the adjusted hazards ratio (95% CI) for each 1% increase in diastolic night:day BP ratio was 1.06 (1.01-1.11). Only one of 33 patients (3.0%) with both a diastolic night:day BP ratio and a 24 h PP below the median progressed, whereas 17 of 32 patients (53.1%) with both a diastolic night:day BP ratio and a 24 h PP equal to or above the median progressed to a more advanced nephropathy stage (p < 0.001). CONCLUSIONS/ INTERPRETATION: Ambulatory PP, impaired nocturnal BP decline and smoking are strong, independent predictors of nephropathy progression in type 2 diabetic patients.
AIMS/HYPOTHESIS: We followed type 2 diabeticpatients over a long period to evaluate the predictive value of ambulatory pulse pressure (PP) and decreased nocturnal BP reduction (non-dipping) for nephropathy progression. METHODS: Type 2 diabeticpatients (n = 112) were followed for an average of 9.5 (range 0.5-14.5) years. At baseline, all patients underwent 24 h ambulatory BP measurement. Urinary albumin excretion rate was evaluated by three urinary albumin:creatinine ratio measurements at baseline and follow-up. RESULTS: At baseline, patients who subsequently progressed to a more advanced nephropathy stage (n = 35) had reduced diastolic night/day BP variation and higher 24 h systolic BP and PP values; they also had more advanced nephropathy and were more likely to smoke than those with no progression of nephropathy (n = 77). In a Cox regression analysis, independent predictors of nephropathy progression were 24 h PP (p < 0.01), diastolic night:day BP ratio (p = 0.02) and smoking (p = 0.02). The adjusted hazards ratio (95% CI) for each mmHg increment in 24 h PP was 1.04 (1.01-1.07), whereas the adjusted hazards ratio (95% CI) for each 1% increase in diastolic night:day BP ratio was 1.06 (1.01-1.11). Only one of 33 patients (3.0%) with both a diastolic night:day BP ratio and a 24 h PP below the median progressed, whereas 17 of 32 patients (53.1%) with both a diastolic night:day BP ratio and a 24 h PP equal to or above the median progressed to a more advanced nephropathy stage (p < 0.001). CONCLUSIONS/ INTERPRETATION: Ambulatory PP, impaired nocturnal BP decline and smoking are strong, independent predictors of nephropathy progression in type 2 diabeticpatients.
Authors: Søren T Knudsen; Toke Bek; Per L Poulsen; Marianne N Hove; Michael Rehling; Carl E Mogensen Journal: Diabetes Care Date: 2002-12 Impact factor: 19.112
Authors: Søren Tang Knudsen; Peter Jeppesen; Christian Alcaraz Frederiksen; Niels Holmark Andersen; Toke Bek; Jørgen Ingerslev; Carl Erik Mogensen; Per Løgstrup Poulsen Journal: J Am Soc Hypertens Date: 2007 May-Jun
Authors: Cristiane B Leitão; Luís H Canani; Patrícia B Polson; Marcel P Molon; Antônio F Pinotti; Jorge L Gross Journal: Diabetes Care Date: 2005-07 Impact factor: 19.112
Authors: Søren T Knudsen; Niels H Andersen; Steen H Poulsen; Hans Eiskjaer; Klavs W Hansen; Kjeld Helleberg; Per L Poulsen; Carl E Mogensen Journal: Am J Hypertens Date: 2008-01-10 Impact factor: 2.689
Authors: Miranda T Schram; Pieter J Kostense; Robert A Van Dijk; Jacqueline M Dekker; Giel Nijpels; Lex M Bouter; Robert J Heine; Coen D Stehouwer Journal: J Hypertens Date: 2002-09 Impact factor: 4.844
Authors: Claudia R L Cardoso; Nathalie C Leite; Guilherme C Salles; Marcel T Ferreira; Gil F Salles Journal: Diabetologia Date: 2017-10-23 Impact factor: 10.122
Authors: Kevin M Wheelock; Mamta Jaiswal; Catherine L Martin; Gudeta D Fufaa; E Jennifer Weil; Kevin V Lemley; Berne Yee; Eva Feldman; Frank C Brosius; William C Knowler; Robert G Nelson; Rodica Pop-Busui Journal: J Diabetes Complications Date: 2016-03-11 Impact factor: 2.852
Authors: M L Marcovecchio; R N Dalton; C P Schwarze; A T Prevost; H A W Neil; C L Acerini; T Barrett; J D Cooper; J Edge; J Shield; B Widmer; J A Todd; D B Dunger Journal: Diabetologia Date: 2009-03-21 Impact factor: 10.122